Related Experiment Video

Updated: Jun 4, 2026

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

Targeting mutant fibroblast growth factor receptors in cancer

Heidi Greulich1, Pamela M Pollock

  • 1Dana-Farber Cancer Institute, Boston, MA 02115, USA. heidig@broadinstitute.org

Trends in Molecular Medicine
|March 4, 2011
PubMed

Insights

Activating mutations in Fibroblast Growth Factor Receptors (FGFRs) cause skeletal disorders and are increasingly linked to cancer. Targeting FGFRs shows promise as a cancer therapy, with ongoing clinical trials.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Fibroblast Growth Factor Receptors (FGFRs) are crucial for cell functions including proliferation, differentiation, and development.
  • Germline mutations in FGFRs are known to cause skeletal developmental disorders.
  • Somatic mutations in FGFRs are increasingly recognized in human cancers, often acting as oncogenic drivers.

Purpose of the Study:

  • To review the role of FGFR mutations in cancer.
  • To highlight the therapeutic potential of targeting FGFRs in oncology.
  • To discuss the development of FGFR-targeted therapies.

Main Methods:

  • Review of existing literature on FGFR mutations in development and cancer.
  • Analysis of preclinical studies using knockdown and pharmaceutical inhibition of FGFRs.
  • Examination of ongoing clinical trials for FGFR-targeted cancer therapies.

Main Results:

  • Gain-of-function FGFR mutations are oncogenic and create dependencies in cancer cells.
  • Preclinical models confirm FGFRs as viable therapeutic targets in cancer.
  • Clinical trials are evaluating both multi-kinase inhibitors and specific pan-FGFR inhibitors.

Conclusions:

  • FGFRs represent a significant therapeutic target in oncology due to their role in cancer development and progression.
  • Targeting FGFRs, through various inhibitors, offers a promising avenue for cancer treatment.
  • The development of specific FGFR inhibitors is advancing cancer therapy research.

More Related Videos

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth06:35

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth

Published on: December 22, 2020

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles08:02

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Published on: May 14, 2021

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...